Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Bioject Medical Technologies Inc.
TIGARD, Ore., Oct. 30, 2013 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into a distribution agreement with FlashMed Inc. a medical supply company based in Quito, Ecuador. FlashMed will be the exclusive distributor of the Biojector® 2000 needle-free injection system and the Bioject® ZetaJet™ portable injector products in Ecuador.
"We are very pleased to have entered into this agreement with FlashMed and we look forward to providing access to our advanced delivery systems to clinicians and patients in Ecuador," said Mark Logomasini, President and CEO of Bioject. "This is Bioject's first entry into South America with our expectation that we will continue to add distribution in the area. FlashMed is a strong, capable partner and this furthers our ability to meet the increasing global demand for needle-free injection systems. Since the beginning of 2013 Bioject has expanded its network into Asia, Australia, the Philippines, the Middle East, and Africa with top tier distributors in all of these regions. In addition to selling commercial devices, these groups are driving innovation for the next important advances in Bioject technology."
About Bioject Medical Technologies Inc.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid able to penetrate skin and deposit medication in the tissue beneath. To meet global demand for needle free injection technologies, Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
Readers and potential investors are cautioned that an investment in the Bioject's securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that the distribution agreement will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the international business. Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.
For more information about Bioject, visit www.bioject.com
©2012 PR Newswire. All Rights Reserved.